Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

BACKGROUND: Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies in England and Wales. Differentiated thyroid cancer (DTC) accounts for ≈94% of all thyroid cancers. Patients with DTC often require treatment with radioactive iodine. Treatment for DTC that is refractory to radio...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Health Technol Assess
Auteurs principaux: Fleeman, Nigel, Houten, Rachel, Bagust, Adrian, Richardson, Marty, Beale, Sophie, Boland, Angela, Dundar, Yenal, Greenhalgh, Janette, Hounsome, Juliet, Duarte, Rui, Shenoy, Aditya
Format: Artigo
Langue:Inglês
Publié: NIHR Journals Library 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983913/
https://ncbi.nlm.nih.gov/pubmed/31931920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta24020
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires